Hows et al. (1983)1717. Hows JM, Chipping PM, Fairhead S, Smith J, Baughan A, Gordon-Smith EC. Nephrotoxicity in bone marrow transplant recipients treated with cyclosporin A. Br J Haematol. 1983;54:69–78.
|
Cohort 4 weeks n = 33 |
Acute nephrotoxicity – serum Cr > 200 μmol/L |
36.4% |
|
|
|
Statistically significant (p-value< 0.001) |
|
|
|
Associated with aminoglycoside |
Kennedy et al. (1983)1818. Kennedy MS, Deeg HJ, Siegel M, Crowley JJ, Storb R, Thomas ED. Acute renal toxicity with combined use of amphotericin B and cyclosporine after marrow transplantation. Transplantation. 1983;35:211–5.
|
RCT 90 days n = 47 |
Acute kidney toxicity – serum Cr≥2× basal |
80.0% |
|
|
|
Statistically significant (p-value<0.01) |
|
|
|
Associated with amphotericin B |
Kennedy et al. (1985)1919. Kennedy MS, Yee GC, Mcguire TR, Leonard TM, Crowley JJ, Deeg HJ. Correlation of serum cyclosporine concentration with renal dysfunction in marrow transplant recipients. Transplantation. 1985;40:249–53.
|
Cohort 60 days n = 63 |
Kidney dysfunction – serum Cr≥2× basal |
86.0% |
|
|
|
Statistically significant (p-value< 0.001) |
|
|
|
Associated with amphotericin B |
Kone et al. (1988)2020. Kone BC, Whelton A, Santos G, Saral R, Watson AJ. Hypertension and renal dysfunction in bone marrow transplant recipients. Q J Med. 1988;69:985–95.
|
RCT Double blind 100 days n = 82 |
Kidney dysfunction – serum Cr elevated |
64.0% |
|
|
|
Cyclosporine is the cause (descriptive analysis) |
|
|
|
Hypertension and associated with hypomagnesemia |
Miller et al. (1994)2121. Miller KB, Schenkein DP, Comenzo R, Erban JK, Fogaren T, Hirsch CA, et al. Adjusted-dose continuous-infusion cyclosporin A to prevent graft-versus-host disease following allogeneic bone marrow transplantation. Ann Hematol. 1994;68:15–20.
|
Cohort 4 weeks n = 45 |
Nephrotoxicity – serum Cr>2mg/dL |
31.0% |
|
|
|
Statistically significant (p-value<0.01) |
|
|
|
Associated with amphotericin B |
Miralbell et al. (1996)2222. Miralbell R, Bieri S, Mermillod B, Helg C, Sancho G, Pastoors B, et al. Renal toxicity after allogeneic bone marrow transplantation: the combined effects of total-body irradiation and graft-versus-host disease. J Clin Oncol. 1996;14:579–85.
|
Cohort – n = 79 |
Kidney dysfunction – serum Cr> 110 μmol/L |
– |
|
|
|
Not significant |
Parikh et al. (2002)2323. Parikh CR, McSweeney PA, Korular D, Ecder T, Merouani A, Taylor J, et al. Renal dysfunction in allogeneic hematopoietic cell transplantation. Kidney Int. 2002;62:566–73.
|
Cohort 1 year n = 88 |
Kidney dysfunction – conventional criteria |
92.0% |
|
|
|
Not significant |
Kishi et al. (2005)2424. Kishi Y, Murashige N, Kami M, Miyakoshi S, Shibagaki Y, Hamaki T, et al. Optimal initial dose of oral cyclosporine in relation to its toxicities for graft-versus-host disease prophylaxis following reduced-intensity stem cell transplantation in Japanese patients. Bone Marrow Transplant. 2005;35:1079–82.
|
Cohort 28 days n = 35 |
Kidney dysfunction – CTC |
54.3% |
|
|
|
Not significant |
Hingorani et al. (2005)99. Hingorani SR, Guthrie K, Batchelder A, Schoch G, Aboulhosn N, Manchion J, et al. Acute renal failure after myeloablative hematopoietic cell transplant: incidence and risk factors. Kidney Int. 2005;67:272–7.
|
Cohort – n = 159 |
ARF – serum Cr ≥ 2× basal |
36.0% |
|
|
|
Not significant |
Caliskan et al. (2006)2525. Caliskan Y, Besisik SK, Sargin D, Ecder T. Early renal injury after myeloablative allogeneic and autologous hematopoietic cell transplantation. Bone Marrow Transplant. 2006;38:141–7.
|
Cohort 100 days n = 47 |
AKI – Conventional criteria |
70.0% |
|
|
|
Statistical significance (p = 0.04) |
|
|
|
Associated with aminoglycoside and amphotericin B (descriptive analysis) |
Kersting et al. (2007)1010. Kersting S, Koomans HA, Hene RJ, Verdonck LF. Acute renal failure after allogeneic myeloablative stem cell transplantation: retrospective analysis of incidence, risk factors and survival. Bone Marrow Transplant. 2007;39:359–65.
|
Cohort 3 months n = 363 |
ARF – conventional criteria |
93.4% |
|
|
|
Not significant |
Lopes et al. (2008)2626. Lopes JA, Gonçalves S, Jorge S, Raimundo M, Resende L, Lourenço F, et al. Contemporary analysis of the influence of acute kidney injury after reduced intensity conditioning haematopoietic cell transplantation on long-term survival. Bone Marrow Transplant. 2008;42:619–26.
|
Cohort 100 days n = 82 |
AKI – RIFLE |
53.6% |
|
|
|
Cyclosporine is the cause (descriptive analysis) |
Kersting et al. (2008)2727. Kersting S, Dorp SV, Theobald M, Verdonck LF. Acute renal failure after nonmyeloablative stem cell transplantation in adults. Biol Blood Marrow Transplant. 2008;14:125–31.
|
Cohort – n = 150 |
ARF – conventional criteria |
94.0% |
|
|
|
Cyclosporine is the cause (descriptive analysis) |
Mae et al. (2008)2828. Mae H, Ooi J, Takahashi S, Tomonari A, Tsukada N, Konuma T, et al. Early renal injury after myeloablative cord blood transplantation in adults. Leuk Lymphoma. 2008;49:538–42.
|
Cohort 100 days n = 54 |
AKI – serum Cr≥ 2× basal |
27.8% |
|
|
|
Not significant |
Pinana et al. (2009)2929. Pinana JL, Valcarcel D, Martino R, Barba P, Moreno E, Sureda A, et al. Study of kidney function impairment after reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation. A single-center experience. Biol Blood Marrow Transplant. 2009;15:21–9.
|
Cohort 1 year n = 188 |
ARF – conventional criteria |
52.0% |
|
|
|
Cyclosporine is the cause (descriptive analysis) |
Saddadi et al. (2010)3030. Saddadi F, Najafi I, Hakemi MS, Falaknazi K, Attari F, Bahar B. Frequency, risk factors, and outcome of acute kidney injury following bone marrow transplantation at Dr Shariati Hospital in Tehran. Iran J Kidney Dis. 2010;4:20–6.
|
Cohort 180 days n = 378 |
AKI – serum Cr≥ 2× basal |
37.6% |
|
|
|
Statistical significance (p-value < 0.001) Associated with amphotericin B |
Kagoya et al. (2011)3131. Kagoya Y, Kataoka K, Nannya Y, Kurokawa M. Pretransplant predictors and posttransplant sequels of acute kidney injury after allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2011;17:394–400.
|
Cohort 100 days n = 207 |
AKI – RIFLE |
76.3% |
|
|
|
Cyclosporine is the cause (descriptive analysis) |
Helal et al. (2011)3232. Helal I, Byzun A, Rerolle JP, Morelon E, Kreis H, Bruneel-Mamzer MF. Acute renal failure following allogeneic hematopoietic cell transplantation: incidence, outcome and risk factors. Saudi J Kidney Dis Transpl. 2011;22:437–43.
|
Cohort 1 year n = 101 |
ARF – serum Cr ≥ 2× basal |
57.4% |
|
|
|
Not significant |
Bao et al. (2011)3333. Bao YS, Xie RJ, Wang M, Feng SZ, Han MZ. An evaluation of the RIFLE criteria for acute kidney injury after myeloablative allogeneic haematopoietic stem cell transplantation. Swiss Med Wkly. 2011;141:w13225.
|
Cohort 100 days n = 143 |
AKI – RIFLE |
48.9% |
|
|
|
Not significant |